Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2024

Yoshizaki Chinatsu, Yoshida Yuki, Nohmi Shiho, Go Yoshihiro, Kusakado Rui, Kawamura Saori, Inoue Daisuke, Kabasawa Nobuyuki, Yamaguchi Fumihiro

Abstract excerpt

Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Factor V Deficiency

Share to Indoles

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 38970909
DOI: 10.1016/j.lungcan.2024.107869

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report.PMID 38970909Read ↗

Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced severe thrombocytopenia: a case report.Semantic proximity Read ↗

Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation.Semantic proximity Read ↗

Disseminated intravascular coagulation complicating diagnosis of ROS1-mutant non-small cell lung cancer: A case report and literature review.Semantic proximity Read ↗

Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib.Semantic proximity Read ↗

Management of nonbacterial thrombotic endocarditis (NBTE) in advanced non-small cell lung cancer (NSCLC) patients with driver mutation: two case reports.Semantic proximity Read ↗

Trousseau's syndrome triggered by an immune checkpoint blockade in a non‐small cell lung cancer patientSemantic proximity Read ↗

Secondary Aplastic Anemia During Osimertinib Treatment for Lung Adenocarcinoma: A Case Report.Semantic proximity Read ↗

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.